

01/31/97

Sheet 1 of 7

Form PTO-1449 INFORMATION: DISCLOSURE CITATION IN: AN APPLICATION (Use several sheets if necessary)			Docket No:					
								iling Date:
			1				NT DOCUMENTS	1 120
Examiner Initial		Document Number	Date	Name	Class	Subclass	Filing Date If Appropriate	
KW	AA	5,587,480	12/24/96	Belleau, et al.	544	310	Тфргорпис	
KW	AB	5,539,116	07/23/96	Liotta and Choi	544	317		
EW.	AC	5,532,246	07/02/96	Belleau, et al.	514	274		
FW	AD	5,486,520	01/23/96	Belleau, et al.	514	274		
*W	AE	5,466,806	11/14/95	Belleau, et al.	544	310		
FW.	AF	5,444,063	08/22/95	Schinazi	514	262		
KW,	AG	5,276,151	01/04/94	Liotta	544	317		
EW	AH	5,270,315	12/14/93	Belleau, et al.	514	262		
KW	Al	5,248,776	09/28/93	Chu, et al.	544	310		
FW	AJ	5,234,913	08/10/93	Furman, Jr., et	514	49		
KIN	AK	5,210,085	05/11/93	Liotta, et al.	514	274		
KW	AL	5,204,466	04/20/93	Liotta, et al.	544	317		
EW	AM	5,185,437	02/09/93	Koszalka, et al.	536	24		
PW	AN	5,179,104	01/12/93	Chu, et al.	544	310		
PW	AO	5,071,983	12/10/91	Koszalka, et al.	544	317		
KM	AP	5,059,690	10/22/91	Zahler, et al.	544	276		
KW.	AQ	5,047,407	09/10/91	Belleau, et al.	514	274		
KW	AR	5,041,449	08/20/91	Belleau, et al.	514	274		
KW	AS	5,011,774	04/30/91	Farina, et al.	435	87		
KW	AT	4,963,533	10/16/90	de Clercq, et al.	514	49		
KW	AU	4,916,122	04/10/90	Chu, et al.	514	50		
KW	AV	4,900,828	02/13/90	Belica, et al.	544	317		
KW	AW	4,879,277	11/07/89	Mitsuya, et al.	514	49		
KW	AX	4,861,759	08/29/89	Hiroaki, et al.	514	46		
KW	AY	4,336,381	06/22/82	Nagata, et al.	544	313		
KW	AZ	4,000,137	12/28/76	Dvonch, et al.	260	252		
KM	AAA	07/686,617	07/02/96	Cheng, et al.				
KW.	AAB	07/718,806	06/21/91	Cheng	_			
KW	AAC	07/785,545	10/31/91	Cheng				
Examiner:	K. 1	Vong		Considered:		 		
EXAMINER not in confo	: Initial if cit mance and	tation considered, whe not considered. Include	ther or not citation the copy of this fo	on is in conformance with Norm with next communication	IPEP § 609 n to the ap	e; Draw line throug plicant.	h citation if	

340639

Sheet 2 of 7

Form PTO-1449			Docket No: EMU108DIV(1)			Application No. 08/488,097				
INFORMATION DISCLOSURE CITATION		CLOSURE	Applicant: Dennis C. Liotta, et al.							
IN AN APPLICATION (Use several sheets if necessary)			Filing Date June 7, 1995			Group Art Unit 1205				
				REIGN PATE						
		Document Numl		Date	Country	C	lass	Subclass	YES	NO
KW.	BA	WO94/1480)2.	07/07/94	PCT			-		
KW.	BB	WO94/0979)3	05/11/94	PCT			-		
KW	BC	WO94/0415	54	03/04/94	PCT		•	(
KW.	/ BD	WO92/2167	76	12/10/92	PCT					
EW	⁄ BE	WO92/1851	17	10/29/92	PCT	T		-,		_
KW	/ BF	WO92/1530)9 \	09/17/92	PCT)		
KW.	√ BG	WO92/1530)8	09/17/92	PCT					
KW	BH	WO92/1474	13	09/03/92	PCT)		
KW	` BI	WO92/1472		09/03/92	PCT		~)		
VIO	BJ	WO92/1049		06/25/92	PCT	·				
EIN	/ BK	WO92/1049	· · · ·	06/25/92	PCT					
KW	/ BL	WO92/0872		05/29/92	PCT)		
KW /	BM	WO91/1715		11/14/91	PCT					
Vs./ /	BN	WO91/1118		08/08/91	PCT			1		
KIN FIN	BO	WO90/1202		10/18/90	PCT	 -				
KW /	BP	WO88/0753		10/06/88	PCT					
F-40	DF	W 000/073	,,,	10/00/00	101					
•		-								
		\ <u></u>								
	<u></u>									
									,	
							*			
Examiner:		Nong		Date Co	nsidered:	102	198			
		on considered, wh		r or not citation is	s in conforman	ce with M	IPEP § 609; [ugh citati	on if

340639

Sheet 3 of 7

Form PTO-14	49	C)ock	et No: EMU108	DIV(1)	Application		<u> </u>	•		
INFORM	INFORMATION DISCLOSURE CITATION			Applicant: Dennis C. Liotta, <i>et al.</i>							
	IN AN APPLICATION (Use several sheets if necessary)			Date: June 7, 1	1995	Group Art I 1205	Group Art Unit 1205				
				FOREIGN PATENT DOCUMENTS							
		Document Number	r	Date	Country	Class	Subclass	YES	NO		
KW.	CA	0 526 253		02/03/93	Europe		_				
KW	CB	0 515 157		11/25/92	Europe		~				
KW	CC	0 515 156		11/25/92	Europe		_				
KIN	CD	0 515 144		11/25/92	Europe		~				
XW	/ CE	0 494 119	T	07/08/92	Europe		~				
KW	CF	0 433 898	T	08/16/90	Europe						
KW.	CG	0 382 526		06/27/90	Europe						
KINI	СН	0 375 329		01/24/90	Europe		,				
KV/	CI	0 361 831		04/04/90	Europe						
KW/	CJ	0 337 713		10/12/88	Europe	~					
XW.	CK	0 217 580		04/08/87	Europe						
FW.	CL	8901258		12/17/90	Netherland	,					
KW/	· CM	07109221	П	04/25/95	Japan						
KW.	CN	2-69469	T	03/08/90	Japan						
KW,	CO	2-69476`		03/08/90	Japan						
	-CP-	73004/91	7		Australia -						
KM	CQ	630913		09/03/92	Australia				-		
KW	- CR	665187		02/20/92	Australia						
EW.	∼ CS	238017		06/27/94	New Zalan						
K.W.	CT	421 636	T	04/10/91	Europe	,					
EW.	CU	357 009		03/07/90	Europe						
KM.	CV	350 811		01/17/90	Europe						
			T								
	ेंच्य										
	· · · · · · · · · · · · · · · · · · ·						<u> </u>				
			T								
			\exists								
Examiner:	Examiner: K. Wan a Date Considered: 0//02/9 8										
EXAMINER:	Initial if citati	on considered, whe	ther	or not citation is	s in conformance wi	th MPEP § 609;	Draw line thro	ugh citati	ion if		
not in conformance and not considered. Include copy of this form with next communication to the applicant.											

* Copy not provided.





Sheet 4 of 7

Form PTO-1449			Docket No: EMU108DIV(1)	Application No. 08/488,097					
			Applicant:						
INFORM	ATION CITA1	DISCLOSURE TION	Dennis C. Liotta, <i>et al.</i>						
IN AN APPLICATION (Use several sheets if necessary)			Filing Date: June 7, 1995	Group Art Unit 1205					
		OTHER DOC	UMENTS (Including Author, Title, Date, Pertin	ent Pages, Etc.)					
KW	DA	Abobo, et al., "	Pharmacokinetics of 2',3'-Dideoxy-5-fluoro Sciences, 83(1):96-99 (1994)						
	np.		iedermann, "Intellectual Property and Chir	rality, Potantability of					
VI	DB	_	f Racemic Drugs in a Racemic Switch Scena	• •					
401		Edinburgh, UK	•	irio, oin chirality conjerence,					
	DC		al., "Potent and Selective Anti-HTLV-III/I	AV Activity of 2' 3'-					
KW1			ene, the 2',3'-Unsaturated Derivative of 2',3	- '					
400		• •	d Biophysical Research Communications, 14						
16.1	DD		, "The enantiomers of 1.betaadenyl-2.alph						
FW1			cl)cyclobutane," Tetrahedron: Asymmetry, 3(
-	DE		d., "Design and Activity of a Novel Class of	· · · · · · · · · · · · · · · · · · ·					
KIZI	ן בי								
70		1989	Against HIV-1," International Conference on AIDS, Montreal, Quebec, Canada, June 4-9,						
	DF		L, "Synthesis and Enzymatic Resolution of	Carbocyclic 2'-Ara-Fluoro-					
Y12 4	`								
400		Guanosine: A Potent New Anti-Herpetic Agent," J. Chem. Soc. Commun., Vol. 10. pp. 656-658 (1988)							
	DG		Activities of (-)-Carbovir and 3'-Azido-3'-D	eoxythymidine Against Human					
			ncy Virus In Vitro," Antimicrobial Agents a	· · · -					
(\ \ \ \ \ \ \ \ \ \ \ \ \ \ \ \ \ \ \									
•	DH	1300 (1990)							
N			3'-Dideoxy-3'-thiacytidine in the Inhibition						
the			The Journal of Biological Chemistry, 267(20):13938-13942 (1992)						
	Di		L, "An Efficient Total Synthesis of 3'-Azido	The second secon					
1 KW 7			Dideoxyuridine (AZDDU, CS-87) from D-M	• • •					
1 .		29(42):5349-53		,					
1-1	DJ		omparative Activity of 2',3'-Saturated and U	Insaturated Pyrimidine and					
KM 7	`		ides Against Human Immunodeficiency Vir						
`			Cells," Biochem. Pharm., 37(19):3543-3548 (
	DK		ructure-Activity Relationships of Pyrimidin						
KIJ 7		Agents for Hur	nan Immunodeficiency Virus Type 1 in Per	ipheral Blood Mononuclear					
44		Cells," J. Med.	Chem., 32:612 (1989)						
,	DL		., "Evaluation of the Potent Anti-Hepatitis						
K17 /		1-[2-(Hydroxyi	nethyl)-1,3-Oxathiolan-5-yl]Cytosine in a N	lovel In Vivo Model,"					
		Antimicrobial A	gents and Chemotherapy, 616-619 (1992)						
KM KM KM	DM		lammer, "Minireview: Antiretroviral Ther						
1 K-W2		Inhibition," An	timicrobial Agents and Chemotherapy, 36(2)	:245-254 (1992)					
111	DN		al., "Catabolism of 3'-Azido-3'-Deoxythymi						
Microsomes, with Evidence of Formation of 3'-Amino-3'-Deoxythymidine, a Highly									
Catabolite for Human Bone Marrow Cells," Molecuilar Pharmacology, 39:258									
Examiner:	V	[1]0 0	Date Considered:						
	۹١,	1/1/1/V	10-1	40					
			ed, whether or not citation is in conformance with MF						

	•		Sheet 5 of 7					
Form PTO-1449		Docket No:: EMU108DIV(1)	Application No 08/488,097					
	N DISCLOSURE ATION	Applicant Dennis C. Liotta, et al.						
	PLICATION eets if necessary)	Filing Date: June 7, 1995	Group Art Unit 1205					
	************************	MENTS (Including Author, Title, Date						
FW EA	and Interactio Chemotherapy	ns with Probenecid in Rhesus Mon., 35(5):801-807 (1991)						
KW/ EB			cation of Hepatitis B Virus in vitro by gues," Natl. Acad. Sci. USA, 88:8495-					
XW EC		"Prevention of activation of HIV-1a. & Chemotherapy, 4(1):55-63 (199.	by antiviral agents in OM-10.1 cells," 3)					
ED			ility, and Metabolic Disposition in Rats					
\ \ \ \ \			athiolan-5-yl] Cytosine, a Nucleoside					
£11,		against Human Immunodeficiency						
		Agents and Chemotherapy, 37(11):2						
EE		, "The Anti-Hepatitis B Virus Activ	· · · · ·					
KM 1		(-) and (+) Enantiomers of cis-5-Flux						
	(1992)	yijCytosiiie, Antimicroviai Agenis	and Chemotherapy, 36(12):2686-2692					
VI. EF		al "Desolution of Aristoromyoin F	Enantiomers," J. Med. Chem., 1985,					
KM 7 Er	Vol. 28, 1385-1	•	mantionicis, J. Med. Chem., 1765,					
EG			e Preparation of Pure Enantiomers of					
XIV 1	the Antiviral Agent 2',3'-Dideoxy-5-fluoro-3'-thiacytidine (FTC) and Related							
		Compounds," J. Org. Chem., 57:5563-5565 (1992)						
C EH		irally Selective Synthesis of Sugar I						
KNA	Chemicoenzymatic Approach: L- and D-Riboses, Showdomycin, and Cordycepin," J.							
	Am. Chem. Soc	Am. Chem. Soc., 103:6739-6741 (1981)						
(El	Jansen, et al.,	"High-Capacity In Vitro Assessmen	nt of Anti-Hepatitis B Virus Compound					
K447	Selectivity by	a Virion-Specific Polymerase Chain Reaction Assay," Antimicrobial						
• •		emotherapy, 441-447 (1993)						
(a\ EJ			ogical Evaluation of B-L-(2R,5S)- and					
KM	, , ,	· •	urine Nucleosides and Potential Anti-					
		J. Med. Chem., 36(2):181-195 (1993	· · · · · · · · · · · · · · · · · · ·					
NY EK			bonucleosides of Some Pyrimidines:					
7-0		Biological Activities," J. Med. Cher.						
EL EL	Research, 97:1	39-146 (1981)	ne D-arabinonucleosides," Carbohydrate					
[C] EM		tent and Selective In Vitro Activity						
KM		• •	n Immunodeficiency Virus," Biochem.					
):2713-2718 (1987)	A. C. H. D (AID 1) At 1					
EN	Mahmoudian,	et al., "Enzymatic Production of U	Optically Pure (2'R-cis)-2'-deoxy-3'-					
KM>		TC, Lamivudine): A Potent Anti-193, Vol. 15, 749-755, published by t	HIV Agent," Enzyme Microb. Technol.,					
	September 19	75, voi. 15, /49-/55, published by the	ne Giaxo Group Research					
EXAMINER: Initial	if citation considered	whether or not citation is in conformance	with MPEP § 609; Draw line through citation if					
		Include copy of this form with next commu						
	1							

K. Wong

1/02/97

d

Sheet 6 of 7

			Sheet 6 of 7			
Form PTO-1449		Docket No.: EMU108DIV(1)	Application No. 08/488,097			
INFORMATION:		Applicant: Dennis C. Liotta, et al.				
IN AN APPL (Use several shee		Filing Date: June 7, 1995	Group Art Unit 1205			
	OTHER DOCU	MENTS (Including Author, Title, Da	te, Pertinent Pages, Etc.)			
Į FA	Mitsuya, H., e	et al., "3'-Azido-3'-Deoxythymidin	e (BW A 509U): An Antiviral Agent			
XM		phadenopathy-Associated Virus I	ect of Human T-Lymphotropic Virus In Vitro, Proc. Natl. Acad. Sci., USA,			
XW FB	A second		S Therapy," Science, Vol. 249, pp. 1533-			
FB FC	HTLV-III/LA	<u>-</u>	Assessing Activity of Agents Against Therapeutic Challenges, S. Broder, Ed.			
(W'FD	1 '	et al., "A New 2',3'-Dideoxynucled "Tetrahedron Lett., 30(46):6263-6	oside Prototype with In Vitro Activity 266 (1989)			
FE FE		Synthetic Studies on Biologically Amatic Approach," <i>Tet. Letters</i> , 40:	•			
FF FF	Okabe, M., et	al., "Synthesis of the Dideoxynuc	leosides ddC and CNT from Glutamic Org. Chem., 53(20):4780-4786 (1988)			
, FG		ntracellular Metabolism of (-)- an				
KW'	Hydroxymeth		in HepG2 Derivative 2.2.15 (Subclone			
· KH FH	Pirkle and Pochansky, "Chiral Stationary Phases for the Direct LC Separation of Enantiomers," <i>Advances in Chromatography</i> , Giddings, J.C., Grushka, E., Brown, P.R., eds.: Marcel Dekker: New York, 1987; Vol. 27, Chap. 3, pp. 73-127					
FI FI		· · · · · · · · · · · · · · · · · · ·	nymidine (AZT) in the Treatment of x," N. Eng. J. Med., 317(4):192-197			
Ch FJ	Roberts, et al.	, "Enzymic Resolution of cis- and" <i>J. Chem Soc.</i> , Perkin Trans.				
, FK			ridinone Derivatives as HIV-1-Specific			
KM	Reverse Tran		of 3-Aminopyridin-2(1H)-one," J. Med.			
KIJ FL	1		-Oxathiolane-5-one Derivatives," <i>Bull</i> ,			
177		pan, 45:913-915 (1972)				
KW FM	Successes-Clin	on-Nucleoside Inhibitors of HIV I nical Failures," <i>Drug Design and I</i>	Discovery, 8:255-263 (1992)			
FN FN	Schinazi, R.F., et al., "Activities of the Four Optical Isomers of 2',3'-Dideoxy-3'- Thiacytidine (BCH-189) against Human Immunodeficiency Virus Type 1 in Human Lymphocytes," Antimicrobial Agents and Chemotherapy 36(3):672-676 (1992)					
KW/FO		., et al., "Insights into HIV Chemo (6):963-990 (1992)	otherapy," AIDS Research and Human			
Examiner:	Mond	Ĭ .	1/02/98			
EXAMINER: Initial if not in conformance an	citation considered in ot considered.	, whether or not citation is in conformand Include copy of this form with next comm	ce with MPEP § 609; Draw line through citation if nunication to the applicant.			

000000000000000000000000000000000000000	0		0.0000000000000000000000000000000000000	Sneet 7 of 7			
Form PTO-	1449		Docket No. EMU108DIV(1)	Application No. 08/488,097			
INFO	INFORMATION DISCLOSURE CITATION		Applicant: Dennis C. Liotta, et al.				
500000000000000000000000000000000000000	N AN APPLIC		Filing Date: June 7, 1995	Group Art Unit			
			MENTS (Including Author, Title, Date, Pertiner				
	GA		, et al., "Pharmacokinetics and Metabolism				
KW.	GA		acytidine in Rhesus Monkeys," Antimicrobi				
	CD		······································	nun alafinianan Viimana L			
1 . 1	GB		, et al., "Selective Inhibition of Human Imr	•			
KM			d Enantiomers of <i>cis-</i> 5-Fluoro-1-[2-(Hydro <i>Antimicrobial Agents and Chemotherapy</i> 36				
	GC	Schinazi, R.F.	, et al., "Substrate Specificity of Escherichi	a Coli Thymidine			
KIL		Phosphorylase	e for Pyrimidine Nucleoside with an Anti-H	luman Immunodeficiency Virus			
1 , 00.		Activity," Bio	chemical Pharmacology 44(2):199-204 (199	2)			
	GD	Secrist, et al.,	"Resolution of Racemic Carbocyclic Analo	gues of Purine Nucleosides			
1×17 -	ŀ	Through the A	Action of Adenosine Deaminase Antiviral A	ctivity of the Carbocyclic 2'-			
		Deoxyguanosi	ne Enantiomers," J. Med. Chem., Vol. 30, p	ор. 746-749 (1987)			
(GE	Shewach, et al	., "Affinity of the antiviral enantiomers of	oxathiolane cytosine			
Kh		nucleosides fo	r human 2'-deoxycytidine kinase," <i>Biochen</i>	n. Pharmacol., 45(7):1540-1543			
1 70,		(1993)					
1/1/	GF	Sterzycki, R.Z	, et al., "Synthesis and anti-HIV activity o	f several 2'-fluoro-containing			
L. C.		pyrimidine nu	ucleosides," J. Med. Chem., 33(8):2150-2157 (1990)				
. 1	GG	Storer, R., et a	d., "The Resolution and Absolute Stereoch	emistry of the Enantiomeris of			
10/1/		cis-1-[2-(Hydr	omethyl)-1,3-Oxathiolan-5-yl)cytosine (BC	CH189): Equipotent Anti-HIV			
1 7 10			eosides & Nucleotides, 12(2):225-236 (1993)				
٠. (،	GH		L, "Solid State Conformation of Anti-Hum				
KM			ts: Crystal Structures of Three 3'-Azido-3'-deoxythymidine Analogues," J.				
			c., 110:2277-2782 (1988)				
111/2	- GI		et al, "Nucleoside Synthesis with Trimethyl	silyl Triflate and Perchlorate as			
KM.			iem. Ber., 114:1234-1255 (1981)				
1 ,, 1	Ğ		"The 5'-Triphosphates of the (1) and (+) E				
I KM \			ethyl)-1,3-Oxathiolane-5-yl]Cytosine Equa				
			ency Virus Type 1 Reverse Transcriptase,"	Antimicrob. Agents and			
			7(8):1720-1722 (1993)				
1.5	GK		et al., "A General Method for Controlling C				
1 KM			is of 2'-Deoxyribose Nucleosides," Tetrahed	tron Lett., 31(13):1815-1818			
<u> </u>		(1990)					
12W-	, GL		et al., "The Synthesis and Anti-HIV Activity	· · · · · · · · · · · · · · · · · · ·			
F 703			Bioorganic & Medicinal Chemistry Letters,				
KW-	ĢМ		, "In vitro susceptibility of clinical isolates				
L	-		protease inhibitor," <i>AIDS</i> , 8:753-756 (1994				
1 KIY	GN '		al., "Cellular Metabolism of 3'-Azido-2',3'-				
1 60.			5'- O-Diphophoshexase Derivatives by Pre	•			
	-00		'- Deoxyuridine Analogs," Molecular Phari				
	-€0 ~		c quired Immune Defictency Syndrome 1921	s, (Kaven Press, Publisher),			
Evaminar	1/ /:	Volume 6 (19	Date Considered:	<i></i>			
Examiner:	$K \cdot (Y_i)$	JONG/	Date Considered. 01/02/	98			
EXAMINER	EXAMINER: Initial if citation considered, whether or not citation is in conformance with MPEP § 609; Draw line through citation if						
	not in confomance and not consider d. Include copy of this form with next communication to the applicant.						

* Copy not provided